Effects of atorvastatin on the prognosis of coronary heart disease patients with chronic heart failure after percutaneous coronary intervention

【Objective】To observe the effects of atorvastatin on the prognosis of coronary heart disease patients with chronic heart failure after percutaneous coronary intervention.【Methods】Ninty-six patients with coronary heart disease were taken to color Doppler before percutaneous coronary intervention,and patients′,left ventricular ejection fraction(LVEF)were50%.They were then assigned to atorvastatin group(n=50)and control group(n=46).Rate of intervation restenosis,LVEF,plasma levels of hypersensitive C-reactive protein and white blood cell were observed after six months.【Results】The rate of percutaneous coronary intervention restenosis in atorvastatin group was much lower than that of the control group(6 % vs 19.57%,P0.05);LVEF in atorvastatin group was also improved(32.88%±1.35% to 52.97%±2.01%,P0.05),but control group had little change(31.76%±1.56% to 38.84%±2.58%,P0.05);the plasma levels of hypersensitive C-reactive protein and white blood cell in two groups were decreased,but atorvastatin group was lower(hsCRR 0.86±0.12 vs 1.66±0.11,P0.05;WBC 6.44±0.88 vs 9.84±1.51,P0.05).【Conclusions】Early Lowering lipid therapy with atorvastatin can decrease the inflammation of the vascular endethelium and the rate of percutaneous coronary intervention restenosis,as well as improve the heart function in patient of coronary heart disease with chronic heart failure after percutaneous coronary intervention.